查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1477394

抗菌藥物抗藥性監測市場 - 全球產業規模、佔有率、趨勢、機會和預測，按解決方案、應用、最終用戶、地區和競爭細分，2019-2029F

Antimicrobial Resistance Surveillance Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Solution, By Application, By End User, By Region, and By Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年，全球抗菌素抗藥性監測市場估值為59.7 億美元，到2029 年，預測期內將以5.88% 的複合年成長率實現令人印象深刻的成長。化方法，用於監測抗菌素抗藥性的流行、趨勢和模式。其主要目標是追蹤抗藥性病原體的出現和傳播，評估抗菌藥物使用對抗藥性發展的影響，並指導抗菌藥物管理和感染控制的實證策略。監測系統收集血液、尿液、呼吸道分泌物和傷口拭子等臨床樣本進行的抗菌藥物敏感性測試 (AST) 的資料。 AST 使用紙片擴散、肉湯微量稀釋、瓊脂稀釋和分子測定等方法評估微生物分離株對特定抗菌藥物的敏感性，包括抗生素、抗病毒藥物、抗真菌藥物和抗寄生蟲藥物。

市場概況
預測期 2025-2029
2023 年市場規模 59.7億美元
2029 年市場規模 84.2億美元
2024-2029 年複合年成長率 5.88%
成長最快的細分市場 診斷試劑盒
最大的市場 北美洲

測試程序受臨床和實驗室標準組織制定的標準化協議和解釋標準管轄。對監測資料的分析揭示了抗菌藥物抗藥性的趨勢，包括隨時間的變化、區域差異以及患者人口統計和醫療保健環境的變化。監測網路促進醫療機構、公共衛生機構、研究機構和國際組織之間的資料共享、協作和資訊交換。他們促進方法標準化、一致的資料報告以及協調一致的應對措施，以在全球範圍內對抗抗菌素抗藥性。

分子診斷、新一代定序和快速即時檢測等診斷技術的進步改變了抗菌藥物抗藥性監測，能夠快速檢測、表徵和監測抗藥性病原體。抗菌藥物管理計劃在醫療機構中變得越來越重要，以鼓勵謹慎使用抗生素並減輕抗藥性感染的傳播。隨著全球化促進抗藥性菌株的快速傳播，監測系統對於監測抗藥性趨勢、發現疫情和實施感染控制措施以防止國際傳播至關重要。

主要市場促進因素

監控工具的技術進步

對抗菌藥物管理計劃的需求不斷成長

新出現的傳染病和流行病

主要市場挑戰

快速演變的抵抗模式

缺乏標準化

主要市場趨勢

即時檢測 (POCT) 解決方案

細分市場洞察

解決方案見解

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球抗菌藥物抗藥性監測市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按解決方案（診斷套件、診斷系統、監控軟體、服務）
    • 按應用（臨床診斷、公共衛生監測、其他應用）
    • 按最終用戶（醫院和診所、研究和學術機構、其他）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖

第 6 章：北美抗菌藥物抗藥性監測市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按解決方案
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲抗菌藥物抗藥性監測市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按解決方案
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區抗菌藥物抗藥性監測市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按解決方案
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲抗菌藥物抗藥性監測市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按解決方案
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲抗菌藥物抗藥性監測市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按解決方案
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最近的發展

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • Luminex Corporation (DiaSorin)
  • Thermo Fisher Scientific Inc
  • Accelerate Diagnostics, Inc.
  • Liofilchem SrI
  • Becton, Dickinson and Company
  • Biomerieux Inc.
  • Bruker Corp.
  • Danaher Corporation
  • Merck KgaA
  • Abbott Laboratories Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 23856

Global Antimicrobial Resistance Surveillance Market was valued at USD 5.97 billion in 2023 and will see an impressive growth in the forecast period at a CAGR of 5.88% tthrough 2029. Antimicrobial Resistance Surveillance is a structured method used to monitor the prevalence, trends, and patterns of antimicrobial resistance (AMR) across different populations and environments. Its main goal is to track the emergence and spread of drug-resistant pathogens, evaluate the impact of antimicrobial use on resistance development, and guide evidence-based strategies for antimicrobial stewardship and infection control. Surveillance systems collect data from antimicrobial susceptibility testing (AST) conducted on clinical specimens such as blood, urine, respiratory secretions, and wound swabs. AST assesses the susceptibility of microbial isolates to specific antimicrobial agents, including antibiotics, antivirals, antifungals, and antiparasitic drugs, using methods like disk diffusion, broth microdilution, agar dilution, and molecular assays.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 5.97 Billion
Market Size 2029USD 8.42 Billion
CAGR 2024-20295.88%
Fastest Growing SegmentDiagnostic kits
Largest MarketNorth America

Testing procedures are governed by standardized protocols and interpretive criteria established by clinical and laboratory standards organizations. Analysis of surveillance data reveals trends in antimicrobial resistance, including changes over time, regional differences, and variations across patient demographics and healthcare settings. Surveillance networks facilitate data sharing, collaboration, and information exchange among healthcare facilities, public health agencies, research institutions, and international organizations. They promote methodological standardization, consistent data reporting, and coordinated responses to combat antimicrobial resistance globally.

Advancements in diagnostic technologies such as molecular diagnostics, next-generation sequencing, and rapid point-of-care testing have transformed antimicrobial resistance surveillance, enabling rapid detection, characterization, and monitoring of drug-resistant pathogens. Antimicrobial stewardship programs have become increasingly important in healthcare facilities to encourage prudent antibiotic use and mitigate the spread of resistant infections. With globalization facilitating the rapid spread of drug-resistant strains, surveillance systems are crucial for monitoring resistance trends, detecting outbreaks, and implementing infection control measures to prevent international transmission.

Key Market Drivers

Technological Advancements in Surveillance Tools

NGS technologies enable rapid and high-throughput sequencing of microbial genomes, facilitating the identification of genetic mutations associated with antimicrobial resistance. NGS allows researchers to analyze entire microbial populations and track the spread of resistant strains with high precision. Molecular diagnostic techniques, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs), enable the rapid detection of specific genetic markers associated with antimicrobial resistance. These techniques provide accurate and timely information about resistance profiles, guiding treatment decisions and infection control measures. Bioinformatics tools and data analytics platforms enable the analysis and interpretation of large-scale genomic data generated by surveillance efforts. Advanced algorithms and computational techniques facilitate the identification of resistance patterns, genetic determinants, and evolutionary pathways of drug-resistant pathogens. Point-of-Care Testing (POCT) devices allow for rapid and on-site detection of antimicrobial resistance in clinical settings, enabling timely treatment decisions and reducing the spread of drug-resistant infections. POCT technologies leverage miniaturized platforms, microfluidics, and integrated sensors to provide real-time results with minimal sample processing.

Whole Genome Sequencing (WGS) technologies provide comprehensive insights into the genetic composition of microbial populations, including antimicrobial resistance genes, virulence factors, and genomic variations. WGS enables detailed molecular characterization of pathogens and facilitates epidemiological investigations, outbreak detection, and surveillance of resistance trends. Mass spectrometry-based methods, such as matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, enable rapid and accurate identification of microbial species and determination of antimicrobial susceptibility profiles. Mass spectrometry platforms offer high throughput and multiplexing capabilities, making them suitable for large-scale surveillance studies. Biosensors and microfluidic devices enable the detection of antimicrobial resistance markers in complex biological samples with high sensitivity and specificity. These miniaturized platforms integrate sensing elements, microfluidic channels, and signal processing components to provide rapid and portable solutions for surveillance applications. This factor will help in the development of the Global Antimicrobial Resistance Surveillance Market.

Growing Need for Antimicrobial Stewardship Programs

Antimicrobial stewardship programs are essential in combating the rising threat of antimicrobial resistance. Surveillance of antimicrobial resistance patterns provides critical data that informs ASPs about the prevalence and trends of resistant pathogens, enabling healthcare facilities to implement targeted interventions to optimize antibiotic use and prevent the spread of resistant infections. Antimicrobial stewardship programs aim to promote judicious and appropriate use of antibiotics to preserve their effectiveness and minimize the development of resistance. Surveillance data helps ASPs monitor antibiotic prescribing practices, identify areas of overuse or misuse, and implement strategies to improve antibiotic prescribing behaviors among healthcare providers. Antimicrobial resistance surveillance data informs empirical therapy guidelines and treatment algorithms by providing insights into local resistance patterns and susceptibility profiles of common pathogens. ASPs use surveillance data to guide the selection of appropriate antibiotics for initial empiric therapy, reducing the risk of treatment failure and the emergence of resistance.

Surveillance of antimicrobial resistance facilitates early detection of outbreaks and emerging resistance trends within healthcare settings and communities. ASPs rely on surveillance data to identify clusters of resistant infections, investigate potential sources of transmission, and implement infection control measures to contain the spread of resistant pathogens. Antimicrobial stewardship programs continuously evaluate the impact of interventions on antibiotic prescribing practices and antimicrobial resistance patterns. Surveillance data allows ASPs to assess the effectiveness of stewardship initiatives, monitor changes in resistance trends over time, and adjust strategies as needed to optimize patient outcomes and minimize the spread of resistance. Many regulatory agencies and accreditation bodies require healthcare facilities to implement antimicrobial stewardship programs as part of efforts to address antimicrobial resistance. Compliance with regulatory requirements necessitates the implementation of robust surveillance systems to monitor antimicrobial use and resistance patterns, driving demand for surveillance solutions in the market. This factor will pace up the demand of the Global Antimicrobial Resistance Surveillance Market.

Emerging Infectious Diseases and Pandemics

During outbreaks of emerging infectious diseases or pandemics, there is often a surge in antibiotic use, both for treating bacterial co-infections and as a precautionary measure. This overuse of antibiotics can contribute to the development and spread of antimicrobial resistance among pathogens, exacerbating the AMR crisis. Emerging infectious diseases and pandemics can complicate treatment protocols by introducing new pathogens or strains with unique resistance profiles. Surveillance of antimicrobial resistance patterns becomes essential for understanding the susceptibility of these pathogens to available antibiotics and guiding treatment decisions. Antimicrobial resistance surveillance helps in the early detection of drug-resistant strains of pathogens associated with emerging infectious diseases and pandemics. Timely identification of resistant strains enables healthcare authorities to implement appropriate infection control measures, prevent further transmission, and optimize treatment strategies to improve patient outcomes.

Surveillance of antimicrobial resistance provides valuable data on the dynamics of resistance development and spread during outbreaks and pandemics. Understanding the patterns of resistance evolution helps public health agencies and healthcare providers anticipate future challenges, adapt treatment protocols, and develop targeted interventions to mitigate the impact of AMR. Effective surveillance of antimicrobial resistance is crucial for preserving the efficacy of antibiotics and other antimicrobial agents used to treat both common and emerging infectious diseases. By monitoring resistance trends and patterns, healthcare systems can implement antimicrobial stewardship programs and infection prevention measures to minimize the selective pressure driving resistance evolution. Emerging infectious diseases and pandemics require coordinated global efforts to monitor, control, and mitigate their impact. Antimicrobial resistance surveillance fosters collaboration among countries, international organizations, and research institutions to share data, resources, and best practices for responding to public health emergencies effectively. This factor will accelerate the demand of the Global Antimicrobial Resistance Surveillance Market.

Key Market Challenges

Rapidly Evolving Resistance Patterns

Pathogens can develop resistance to antimicrobial agents through various mechanisms, including genetic mutations, horizontal gene transfer, and the acquisition of mobile genetic elements. The diverse and evolving nature of resistance mechanisms makes it challenging to predict and track changes in resistance patterns accurately. New and unexpected resistance mechanisms can emerge over time, rendering existing surveillance methods and assays ineffective in detecting and characterizing resistant strains. The identification of novel resistance mechanisms requires continuous research and development efforts to update surveillance tools and technologies accordingly. Drug-resistant pathogens can spread rapidly within and across healthcare settings, communities, and geographic regions. The global dissemination of resistant strains complicates surveillance efforts and necessitates international collaboration and data sharing to monitor resistance trends and prevent the spread of resistant infections. The selective pressure exerted by the widespread use and misuse of antibiotics accelerates the development and spread of antimicrobial resistance. Antibiotic exposure drives the selection of resistant bacterial populations, leading to the emergence of multidrug-resistant strains that are difficult to treat and control. Pathogens have the capacity to adapt and evolve in response to environmental pressures, including exposure to antimicrobial agents. The adaptive evolution of pathogens allows them to develop mechanisms to evade the effects of antibiotics, leading to the persistence and proliferation of resistant strains in clinical and community settings. Resistance patterns can vary widely among different pathogens, patient populations, and geographic locations. The heterogeneity of resistance patterns presents challenges in standardizing surveillance methods, interpreting surveillance data, and implementing targeted interventions to address specific resistance threats effectively.

Lack of Standardization

There is a lack of standardized protocols and methodologies for data collection, analysis, and reporting across different regions, healthcare settings, and surveillance programs. This inconsistency makes it difficult to compare and interpret surveillance data accurately, hindering efforts to monitor antimicrobial resistance trends on a global scale. Variability in testing procedures, including antimicrobial susceptibility testing methods, interpretive criteria, and quality control measures, can lead to discrepancies in resistance data reported by different laboratories and surveillance systems. Without standardized testing protocols, the reliability and comparability of surveillance data are compromised. Surveillance infrastructure varies widely among countries and healthcare systems, resulting in disparities in surveillance capabilities and data quality. Resource-limited settings may lack the necessary laboratory facilities, trained personnel, and data management systems to conduct robust antimicrobial resistance surveillance effectively. The lack of standardized data formats, interoperable systems, and secure platforms for data sharing and integration hinders collaboration and information exchange among stakeholders involved in antimicrobial resistance surveillance. Fragmented data silos impede efforts to track resistance trends, identify emerging threats, and coordinate response strategies across borders and sectors. Differences in definitions, terminologies, and classification schemes used to describe antimicrobial resistance phenotypes and resistance mechanisms can lead to confusion and misinterpretation of surveillance data. Harmonizing terminology and standardizing nomenclature are essential for ensuring consistency and accuracy in resistance surveillance reporting.

Key Market Trends

Point-of-Care Testing (POCT) Solutions

Point-of-care testing (POCT) solutions facilitate swift and on-site detection of antimicrobial resistance in clinical environments, enabling healthcare providers to promptly determine treatment courses. This rapid access to test results expedites the commencement of appropriate antibiotic therapy, leading to enhanced patient outcomes and reduced spread of drug-resistant infections. Unlike conventional laboratory-based antimicrobial susceptibility testing (AST) methods, which often involve lengthy turnaround times, POCT solutions offer near-real-time results, minimizing delays in diagnosis and allowing healthcare providers to promptly select the most effective antibiotics.

POCT solutions support personalized and precision medicine approaches by furnishing actionable insights into antimicrobial resistance patterns and susceptibility profiles. This empowers healthcare providers to customize antibiotic therapy based on individual patient characteristics, resistance profiles, and local epidemiology, thereby optimizing treatment effectiveness while mitigating adverse effects and the development of antimicrobial resistance. The rapid identification of drug-resistant pathogens through POCT solutions enables early detection of outbreaks and the implementation of infection control measures to curtail further transmission. By facilitating prompt isolation of infected patients, cohorting strategies, and targeted antimicrobial prophylaxis, POCT solutions help mitigate the risk of healthcare-associated infections and contain the spread of antimicrobial resistance.

POCT solutions empower frontline healthcare providers, including physicians, nurses, and pharmacists, to make well-informed treatment decisions at the bedside or in outpatient settings. By integrating antimicrobial resistance surveillance into routine clinical practice, POCT solutions promote antimicrobial stewardship, antibiotic optimization, and evidence-based prescribing practices.

Segmental Insights

Solution Insights

The Diagnostic kits segment is projected to experience rapid growth in the Global Antimicrobial Resistance Surveillance Market during the forecast period. With the global rise in antimicrobial resistance (AMR), there is a growing need for rapid and accurate diagnostic tools to identify drug-resistant pathogens. Diagnostic kits play a crucial role in detecting antimicrobial resistance patterns and guiding appropriate treatment decisions. There is a growing demand for point-of-care testing (POCT) solutions that enable rapid detection of antimicrobial resistance in clinical settings. Diagnostic kits that offer quick and reliable results at the point of care facilitate timely treatment decisions, reduce the spread of drug-resistant infections, and improve patient outcomes. Advances in diagnostic technologies, such as molecular diagnostics, next-generation sequencing, and phenotypic testing methods, have led to the development of innovative diagnostic kits for antimicrobial resistance surveillance. These technologies enhance the speed, sensitivity, and specificity of resistance detection, allowing healthcare providers to tailor treatment regimens based on resistance profiles. Governments and regulatory agencies worldwide are implementing initiatives to address antimicrobial resistance and promote the development and adoption of diagnostic solutions. Regulatory support for innovative diagnostic kits, expedited approval processes, and reimbursement policies incentivize investment in this segment of the market. Healthcare professionals, policymakers, and the public are becoming increasingly aware of the importance of antimicrobial resistance surveillance and the role of diagnostic kits in combating AMR. Educational campaigns, awareness programs, and training initiatives highlight the benefits of early detection and appropriate management of drug-resistant infections.

Regional Insights

North America emerged as the dominant region in the Global Antimicrobial Resistance Surveillance Market in 2023. North America boasts advanced healthcare infrastructure, including well-established surveillance systems and sophisticated laboratory facilities. These resources enable comprehensive monitoring and analysis of antimicrobial resistance patterns. The region is home to numerous pharmaceutical and biotechnology companies that are actively engaged in research and development activities related to antimicrobial resistance surveillance. Investments in innovative technologies and collaborations with academic institutions contribute to the advancement of surveillance capabilities. North America has stringent regulatory frameworks governing antimicrobial resistance surveillance, which promote adherence to standardized methods and protocols. Regulatory agencies such as the Centers for Disease Control and Prevention (CDC) in the United States play a key role in coordinating surveillance efforts and disseminating critical information to healthcare providers and policymakers. There is a high level of awareness among healthcare professionals, policymakers, and the public about the threats posed by antimicrobial resistance in North America. Consequently, there is strong political will to allocate funding and resources toward surveillance initiatives aimed at combating drug-resistant pathogens.

Key Market Players

Luminex Corporation (DiaSorin)

Thermo Fisher Scientific Inc

Accelerate Diagnostics, Inc.

Liofilchem S.r.I.

Becton, Dickinson, and Company

Biomerieux Inc.

Bruker Corp.

Danaher Corporation

Merck KgaA

Abbott Laboratories Inc.

Report Scope:

In this report, the Global Antimicrobial Resistance Surveillance Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antimicrobial Resistance Surveillance Market, By Solution:

    Diagnostic kits Diagnostic systems Surveillance software Services

Antimicrobial Resistance Surveillance Market, By Application:

    Clinical Diagnostics Public Health Surveillance Other Applications

Antimicrobial Resistance Surveillance Market, By End User:

    Hospitals & Clinics Research & Academic Institutes Others

Antimicrobial Resistance Surveillance Market, By Region:

    North America

United States

Canada

Mexico

    Europe

Germany

United Kingdom

France

Italy

Spain

    Asia-Pacific

China

Japan

India

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Antimicrobial Resistance Surveillance Market.

Available Customizations:

Global Antimicrobial Resistance Surveillance market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antimicrobial Resistance Surveillance Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Solution (Diagnostic kits, Diagnostic systems, Surveillance software, Services)
    • 5.2.2. By Application (Clinical Diagnostics, Public Health Surveillance, Other Applications)
    • 5.2.3. By End User (Hospitals & Clinics, Research & Academic Institutes, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2023)
  • 5.3. Market Map

6. North America Antimicrobial Resistance Surveillance Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Solution
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Antimicrobial Resistance Surveillance Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Solution
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Antimicrobial Resistance Surveillance Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Solution
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Antimicrobial Resistance Surveillance Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Solution
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Antimicrobial Resistance Surveillance Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Solution
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Antimicrobial Resistance Surveillance Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Solution
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. United Kingdom Antimicrobial Resistance Surveillance Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Solution
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. Italy Antimicrobial Resistance Surveillance Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Solution
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. France Antimicrobial Resistance Surveillance Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Solution
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Antimicrobial Resistance Surveillance Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Solution
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia-Pacific Antimicrobial Resistance Surveillance Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Solution
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Antimicrobial Resistance Surveillance Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Solution
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Antimicrobial Resistance Surveillance Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Solution
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Antimicrobial Resistance Surveillance Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Solution
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Antimicrobial Resistance Surveillance Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Solution
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Antimicrobial Resistance Surveillance Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Solution
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. South America Antimicrobial Resistance Surveillance Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Solution
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Antimicrobial Resistance Surveillance Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Solution
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Antimicrobial Resistance Surveillance Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Solution
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Antimicrobial Resistance Surveillance Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Solution
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. Middle East and Africa Antimicrobial Resistance Surveillance Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Solution
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Antimicrobial Resistance Surveillance Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Solution
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Antimicrobial Resistance Surveillance Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Solution
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Antimicrobial Resistance Surveillance Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Solution
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Luminex Corporation (DiaSorin)
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Thermo Fisher Scientific Inc
  • 14.3. Accelerate Diagnostics, Inc.
  • 14.4. Liofilchem S.r.I.
  • 14.5. Becton, Dickinson and Company
  • 14.6. Biomerieux Inc.
  • 14.7. Bruker Corp.
  • 14.8. Danaher Corporation
  • 14.9. Merck KgaA
  • 14.10.Abbott Laboratories Inc.

15. Strategic Recommendations

16. About Us & Disclaimer